Cargando…

Clinical and prognostic implications of an immune‐related risk model based on TP53 status in lung adenocarcinoma

TP53 mutation is the most widespread mutation in lung adenocarcinoma (LUAD). Meanwhile, p53 (encoded by TP53) has recently been implicated in immune responses. However, it is still unknown whether TP53 mutation remodels the tumour microenvironment to influence tumour progression and prognosis in LUA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Xuming, Chen, Qiang, Wang, Jifan, Mao, Qixing, Xia, Wenjie, Xu, Lin, Jiang, Feng, Dong, Gaochao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743672/ https://www.ncbi.nlm.nih.gov/pubmed/34877770 http://dx.doi.org/10.1111/jcmm.17097

Ejemplares similares

Aberrant super-enhancer landscape reveals core transcriptional regulatory circuitry in lung adenocarcinoma
por: Zhang, Te, et al.
Publicado: (2020)

Establishing an 8‐gene immune prognostic model based on TP53 status for lung adenocarcinoma
por: Wu, Guodong, et al.
Publicado: (2022)

DNA methylation mediated silencing of microRNA-145 is a potential prognostic marker in patients with lung adenocarcinoma
por: Xia, Wenjie, et al.
Publicado: (2015)

circDCUN1D4 suppresses tumor metastasis and glycolysis in lung adenocarcinoma by stabilizing TXNIP expression
por: Liang, Yingkuan, et al.
Publicado: (2020)

A novel gene expression signature-based on B-cell proportion to predict prognosis of patients with lung adenocarcinoma
por: Zhang, Yi, et al.
Publicado: (2021)

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

Non-genetic stratification reveals epigenetic heterogeneity and identifies vulnerabilities of glycolysis addiction in lung adenocarcinoma subtype
por: Song, Xuming, et al.
Publicado: (2022)

Immune landscape and a promising immune prognostic model associated with TP53 in early‐stage lung adenocarcinoma
por: Wu, Chengde, et al.
Publicado: (2020)

CT-Based Deep Learning Model for Invasiveness Classification and Micropapillary Pattern Prediction Within Lung Adenocarcinoma
por: Ding, Hanlin, et al.
Publicado: (2020)

A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma
por: Zhang, Xiaonan, et al.
Publicado: (2022)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

The super-enhancer-driven lncRNA LINC00880 acts as a scaffold between CDK1 and PRDX1 to sustain the malignance of lung adenocarcinoma
por: Feng, Yipeng, et al.
Publicado: (2023)

Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma
por: Feng, Juan, et al.
Publicado: (2023)

Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway
por: Zhang, Te, et al.
Publicado: (2022)

A network-based signature to predict the survival of non-smoking lung adenocarcinoma
por: Mao, Qixing, et al.
Publicado: (2018)

The TWIST1-centered competing endogenous RNA network promotes proliferation, invasion, and migration of lung adenocarcinoma
por: Xia, Wenjie, et al.
Publicado: (2019)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation
por: Fu, Jing, et al.
Publicado: (2021)

CircCNTNAP3-TP53-positive feedback loop suppresses malignant progression of esophageal squamous cell carcinoma
por: Wang, Hui, et al.
Publicado: (2020)

Circular RNA circCRIM1 inhibits invasion and metastasis in lung adenocarcinoma through the microRNA (miR)‐182/miR‐93‐leukemia inhibitory factor receptor pathway
por: Wang, Lin, et al.
Publicado: (2019)

Construction and Validation of an Immune-Related Prognostic Model Based on TP53 Status in Colorectal Cancer
por: Zhao, Xiaojuan, et al.
Publicado: (2019)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy
por: Chen, Yuzhong, et al.
Publicado: (2023)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

Upregulated Collagen COL10A1 Remodels the Extracellular Matrix and Promotes Malignant Progression in Lung Adenocarcinoma
por: Liang, Yingkuan, et al.
Publicado: (2020)

TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival
por: Freudenstein, Donald, et al.
Publicado: (2020)

Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
por: Zeng, Dejun, et al.
Publicado: (2021)

The Long Noncoding RNA LINC00665 Facilitates c-Myc Transcriptional Activity via the miR-195-5p MYCBP Axis to Promote Progression of Lung Adenocarcinoma
por: Wang, Anpeng, et al.
Publicado: (2021)

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

Glypican-5 suppresses Epithelial-Mesenchymal Transition of the lung adenocarcinoma by competitively binding to Wnt3a
por: Wang, Siwei, et al.
Publicado: (2016)

The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis
por: Fisher, Oliver M, et al.
Publicado: (2017)

Tertiary lymphoid structures favor outcome in resected esophageal squamous cell carcinoma
por: Li, Rutao, et al.
Publicado: (2022)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

A case report of low grade fetal lung adenocarcinoma with TP53 mutation
por: Wang, Bo, et al.
Publicado: (2022)

Gut Microbiota Shapes the Efficiency of Cancer Therapy
por: Ma, Weidong, et al.
Publicado: (2019)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

Improvement of survival for non-small cell lung cancer over time
por: Xia, Wenjie, et al.
Publicado: (2017)

Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-Analysis
por: Qixing, Mao, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9poa2pgpofp4u3788v45a1js8s